IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...

IRVING, Texas, May 07, 2025--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital ...

This article first appeared on GuruFocus. Biote Corp (NASDAQ:BTMD) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $47.76 million, and the earnings ...

IRVING, Texas - Biote Corp. (NASDAQ: BTMD), a preventive health care company specializing in personalized hormone optimization, has reached a settlement with its founder, Dr. Gary S. Donovitz, ...

CEO Bret Christensen noted that "the second quarter was pivotal for Biote as we implemented a strategic organizational restructuring designed to drive increased and sustainable growth." He highlighted ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...